-$1.30 Earnings Per Share Expected for Tandem Diabetes Care Inc (TNDM) This Quarter
Equities analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to post ($1.30) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($1.21) and the lowest estimate coming in at ($1.37). Tandem Diabetes Care reported earnings of ($4.80) per share during the same quarter last year, which suggests a positive year over year growth rate of 72.9%. The business is expected to report its next quarterly earnings report on Wednesday, March 14th.
On average, analysts expect that Tandem Diabetes Care will report full-year earnings of ($15.37) per share for the current year, with EPS estimates ranging from ($16.99) to ($13.31). For the next fiscal year, analysts forecast that the firm will post earnings of ($5.72) per share, with EPS estimates ranging from ($10.40) to ($2.87). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, October 26th. The medical device company reported ($3.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.74) by $0.65. The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.92 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. The company’s quarterly revenue was up 119.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.97) EPS.
Several analysts recently commented on TNDM shares. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a report on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a report on Friday, October 6th. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price objective (down previously from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Tandem Diabetes Care in a report on Sunday, November 19th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $11.29.
In other news, CEO Kim D. Blickenstaff acquired 285,700 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The stock was bought at an average price of $3.50 per share, with a total value of $999,950.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 20.90% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in TNDM. Bank of America Corp DE grew its holdings in Tandem Diabetes Care by 88.6% during the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock valued at $1,032,000 after purchasing an additional 404,452 shares during the period. Russell Investments Group Ltd. grew its holdings in Tandem Diabetes Care by 93.3% during the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock valued at $465,000 after purchasing an additional 280,551 shares during the period. Wedbush Securities Inc. grew its holdings in Tandem Diabetes Care by 88.6% during the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock valued at $138,000 after purchasing an additional 88,709 shares during the period. Keybank National Association OH grew its holdings in Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after purchasing an additional 72,177 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after purchasing an additional 32,991 shares during the period.
Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded down $0.10 on Thursday, hitting $2.40. The company had a trading volume of 287,905 shares, compared to its average volume of 200,990. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. Tandem Diabetes Care has a one year low of $2.15 and a one year high of $30.00.
COPYRIGHT VIOLATION WARNING: “-$1.30 Earnings Per Share Expected for Tandem Diabetes Care Inc (TNDM) This Quarter” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/1-30-earnings-per-share-expected-for-tandem-diabetes-care-inc-tndm-this-quarter/1750426.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.